Gene therapy targeting blood vessel growth improves psoriasis
Göttingen/Paris – Researchers from Germany, Denmark and French BioAlliance Pharma S.A have found that reducing angiogenesis in xenotransplantation models of psoriasis and in mice with a disease that resembles psoriasis alleviates disease (J Clin Invest. doi:10.1172/JCI41295). When the team headed by Michael P. Schön (Göttingen University) treated 3 different transgenic mouse models with a non-viral vector expressing recombinant disintegrin domain (RDD) of metargidin (also known as ADAM-15) in muscles, cutaneous angiogenesis and vascularization were reduced in all of them. High-resolution ultrasound revealed reduced cutaneous blood flow in vivo after electroporation with RDD but not with control plasmids. In addition, angiogenesis- and inflammation-related molecular markers, keratinocyte proliferation, epidermal thickness, and clinical disease scores were downregulated in all models. The researchers believe that non-viral antiangiogenic gene therapy helps alleviating psoriasis and may do so in other angiogenesis-related inflammatory skin disorders.